1. Home
  2. RHE vs GRI Comparison

RHE vs GRI Comparison

Compare RHE & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RHE
  • GRI
  • Stock Information
  • Founded
  • RHE 1988
  • GRI 2018
  • Country
  • RHE United States
  • GRI United States
  • Employees
  • RHE N/A
  • GRI N/A
  • Industry
  • RHE Real Estate
  • GRI Biotechnology: Pharmaceutical Preparations
  • Sector
  • RHE Real Estate
  • GRI Health Care
  • Exchange
  • RHE Nasdaq
  • GRI Nasdaq
  • Market Cap
  • RHE 3.5M
  • GRI 3.0M
  • IPO Year
  • RHE 2006
  • GRI N/A
  • Fundamental
  • Price
  • RHE $1.57
  • GRI $0.77
  • Analyst Decision
  • RHE
  • GRI Strong Buy
  • Analyst Count
  • RHE 0
  • GRI 1
  • Target Price
  • RHE N/A
  • GRI $12.00
  • AVG Volume (30 Days)
  • RHE 27.3K
  • GRI 9.9M
  • Earning Date
  • RHE 11-29-2024
  • GRI 11-14-2024
  • Dividend Yield
  • RHE N/A
  • GRI N/A
  • EPS Growth
  • RHE N/A
  • GRI N/A
  • EPS
  • RHE N/A
  • GRI N/A
  • Revenue
  • RHE $15,936,000.00
  • GRI N/A
  • Revenue This Year
  • RHE N/A
  • GRI N/A
  • Revenue Next Year
  • RHE N/A
  • GRI N/A
  • P/E Ratio
  • RHE N/A
  • GRI N/A
  • Revenue Growth
  • RHE N/A
  • GRI N/A
  • 52 Week Low
  • RHE $1.13
  • GRI $0.30
  • 52 Week High
  • RHE $3.08
  • GRI $106.29
  • Technical
  • Relative Strength Index (RSI)
  • RHE 43.01
  • GRI 49.32
  • Support Level
  • RHE $1.13
  • GRI $0.79
  • Resistance Level
  • RHE $2.11
  • GRI $1.00
  • Average True Range (ATR)
  • RHE 0.15
  • GRI 0.17
  • MACD
  • RHE -0.04
  • GRI -0.02
  • Stochastic Oscillator
  • RHE 44.90
  • GRI 24.95

About RHE Regional Health Properties Inc.

Regional Health Properties Inc is a self-managed healthcare real estate investment company that invests in real estate purposed for senior living and long-term healthcare through facility lease and sub-lease transactions. It has two reportable segments real estate segment and the healthcare services segment. It derives the majority of its revenue from the healthcare services segment. Its portfolio of properties is diversified across various states, with concentrations in Georgia and Ohio.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: